https://www.nasdaq.com/press-release/longboard-pharmaceuticals-to-present-at-the-h.c.-wainwright-bioconnect-virtual
https://www.nasdaq.com/press-release/arena-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-20
https://www.nasdaq.com/press-release/shareholder-notice%3a-brodsky-smith-announces-an-investigation-of-arena-pharmaceuticals
https://www.nasdaq.com/press-release/pfizer-to-acquire-arena-pharmaceuticals-2021-12-13
https://www.nasdaq.com/press-release/arena-pharmaceuticals-achieves-target-enrollment-for-etrasimod-cultivate-study-a-2021
https://www.nasdaq.com/press-release/longboard-pharmaceuticals-appoints-life-sciences-executive-dr.-jane-tiller-to-board
https://www.nasdaq.com/press-release/arena-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-19
https://www.nasdaq.com/press-release/longboard-pharmaceuticals-to-participate-in-upcoming-investor-conferences-2021-11-11
https://www.nasdaq.com/press-release/arena-reports-third-quarter-financial-results-and-key-program-updates-2021-11-04
https://www.nasdaq.com/press-release/longboard-pharmaceuticals-provides-corporate-update-and-reports-third-quarter-2021
https://www.nasdaq.com/press-release/longboard-pharmaceuticals-announces-steven-w.-spector-joins-the-company-as-general
https://www.nasdaq.com/press-release/arena-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-18
https://www.nasdaq.com/press-release/arena-pharmaceuticals-to-release-third-quarter-2021-financial-results-and-provide
https://www.nasdaq.com/press-release/longboard-pharmaceuticals-to-present-at-the-cantor-virtual-global-healthcare
https://www.nasdaq.com/press-release/arena-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-17
https://www.nasdaq.com/press-release/longboard-pharmaceuticals-successfully-completes-lp352-multiple-ascending-dose
https://www.nasdaq.com/press-release/arena-pharmaceuticals-to-host-virtual-rd-investor-calls-and-participate-in-upcoming
https://www.nasdaq.com/press-release/longboard-pharmaceuticals-to-present-at-two-upcoming-investor-conferences-2021-08-31
https://www.nasdaq.com/press-release/arena-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-16
https://www.nasdaq.com/press-release/longboard-pharmaceuticals-provides-corporate-update-and-reports-second-quarter-2021
https://www.nasdaq.com/press-release/arena-reports-second-quarter-financial-results-and-key-program-updates-2021-08-05
https://www.nasdaq.com/press-release/second-genome-announces-collaboration-with-arena-pharmaceuticals-to-identify
https://www.nasdaq.com/press-release/arena-pharmaceuticals-to-release-second-quarter-2021-financial-results-and-provide
https://www.nasdaq.com/press-release/arena-pharmaceuticals-and-aristea-therapeutics-establish-collaboration-for
https://www.nasdaq.com/press-release/arena-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-15
https://www.nasdaq.com/press-release/arena-pharmaceuticals-appoints-doug-manion-m.d.-f.r.c.p.-c-as-executive-vice
https://www.nasdaq.com/press-release/arena-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-14
https://www.nasdaq.com/press-release/steven-schoch-elected-to-arena-pharmaceuticals-board-of-directors-2021-06-14
https://www.nasdaq.com/press-release/arena-pharmaceuticals-announces-orphan-drug-designation-for-etrasimod-for-the
https://www.nasdaq.com/press-release/arena-pharmaceuticals-announces-first-participant-randomized-in-phase-2-trial
https://www.nasdaq.com/press-release/arena-pharmaceuticals-earns-a-rating-from-msci-esg-a-leading-rating-agency-for
https://www.nasdaq.com/press-release/arena-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-13
https://www.nasdaq.com/press-release/arena-pharmaceuticals-earns-prime-status-from-iss-esg-a-leading-rating-agency-for
https://www.nasdaq.com/press-release/longboard-pharmaceuticals-provides-corporate-update-and-reports-first-quarter-2021
https://www.nasdaq.com/press-release/arena-reports-first-quarter-financial-results-with-strong-cash-position-and-continued
https://www.nasdaq.com/press-release/arena-pharmaceuticals-to-release-first-quarter-2021-financial-results-and-provide
https://www.nasdaq.com/press-release/arena-pharmaceuticals-presents-clinician-and-patient-reported-outcomes-data-from
https://www.nasdaq.com/press-release/arena-pharmaceuticals-releases-second-annual-environmental-social-and-governance-esg
https://www.nasdaq.com/press-release/arena-pharmaceuticals-to-present-data-from-the-phase-2b-advise-trial-during-late
https://www.nasdaq.com/press-release/arena-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-12
https://www.nasdaq.com/press-release/arena-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-11
https://www.nasdaq.com/press-release/longboard-pharmaceuticals-announces-pricing-of-initial-public-offering-2021-03-11
https://www.nasdaq.com/press-release/arena-pharmaceuticals-reports-topline-results-from-phase-2b-captivate-clinical-trial
https://www.nasdaq.com/press-release/arena-reports-fourth-quarter-financial-results-with-strong-liquidity-position-and
https://www.nasdaq.com/press-release/arena-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-10
https://www.nasdaq.com/press-release/arena-pharmaceuticals-to-release-fourth-quarter-full-year-2020-financial-results-and
https://www.nasdaq.com/press-release/arena-pharmaceuticals-announces-changes-to-board-of-directors-2021-02-16
https://www.nasdaq.com/press-release/arena-pharmaceuticals-completes-full-enrollment-of-etrasimod-phase-3-elevate-uc-52
https://www.nasdaq.com/press-release/arena-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2021
https://www.nasdaq.com/press-release/arena-pharmaceuticals-to-present-at-the-j.p.-morgan-healthcare-conference-on-january
https://www.nasdaq.com/press-release/arena-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-9
https://www.nasdaq.com/press-release/arena-pharmaceuticals-to-present-data-from-the-phase-2b-advise-trial-late-breaker-at
https://www.nasdaq.com/press-release/arena-pharmaceuticals-achieves-target-enrollment-for-etrasimod-phase-3-elevate-uc-52
https://www.nasdaq.com/press-release/arena-pharmaceuticals-announces-rd-leadership-transition-2020-11-30
https://www.nasdaq.com/press-release/arena-pharmaceuticals-to-present-at-the-evercore-isi-healthconx-conference-on
https://www.nasdaq.com/press-release/arena-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-8
https://www.nasdaq.com/press-release/arena-reports-third-quarter-financial-results-with-strong-cash-position-advancing
https://www.nasdaq.com/press-release/arena-pharmaceuticals-advancing-etrasimod-into-phase-3-program-in-atopic-dermatitis
https://www.nasdaq.com/press-release/arena-pharmaceuticals-to-release-third-quarter-2020-financial-results-and-provide
https://www.nasdaq.com/press-release/arena-pharmaceuticals-announces-launch-of-longboard-pharmaceuticals-with-%2456m
https://www.nasdaq.com/press-release/arena-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7
https://www.nasdaq.com/press-release/arena-pharmaceuticals-presence-at-united-european-gastroenterology-week-strengthens
https://www.nasdaq.com/press-release/arena-pharmaceuticals-completes-full-enrollment-of-olorinab-phase-2-captivate-trial
https://www.nasdaq.com/press-release/arena-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-6
https://www.nasdaq.com/press-release/arena-pharmaceuticals-to-present-at-the-jefferies-virtual-next-generation-ibd
https://www.nasdaq.com/press-release/arena-pharmaceuticals-announces-first-subject-dosed-in-elevate-uc-12-global-phase-3
https://www.nasdaq.com/press-release/arena-pharmaceuticals-to-participate-in-upcoming-investor-conferences-2020-09-03
https://www.nasdaq.com/press-release/arena-pharmaceuticals-announces-first-subject-dosed-in-phase-2-trial-evaluating
https://www.nasdaq.com/press-release/arena-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-5
https://www.nasdaq.com/press-release/arena-reports-second-quarter-financial-results-with-strong-liquidity-position-and-0
https://www.nasdaq.com/press-release/arena-pharmaceuticals-to-release-second-quarter-2020-financial-results-and-provide
https://www.nasdaq.com/press-release/arena-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4
https://www.nasdaq.com/press-release/arena-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-3
https://www.nasdaq.com/press-release/arena-pharmaceuticals-appoints-biotech-executive-katharine-knobil-m.d.-to-board-of
https://www.nasdaq.com/press-release/arena-pharmaceuticals-announces-rd-leadership-transition-2020-06-08
https://www.nasdaq.com/press-release/arena-pharmaceuticals-announces-completion-of-public-offering-of-common-stock-and
https://www.nasdaq.com/press-release/arena-pharmaceuticals-announces-pricing-of-public-offering-of-common-stock-2020-05-28
https://www.nasdaq.com/press-release/arena-pharmaceuticals-announces-proposed-public-offering-of-common-stock-2020-05-27
https://www.nasdaq.com/press-release/arena-completes-full-enrollment-of-etrasimod-phase-2-advise-trial-for-atopic
https://www.nasdaq.com/press-release/arena-announces-change-to-virtual-format-for-2020-annual-meeting-of-stockholders-2020
https://www.nasdaq.com/press-release/arena-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2
https://www.nasdaq.com/press-release/arena-pharmaceuticals-to-participate-in-upcoming-investor-conferences-2020-05-13
https://www.nasdaq.com/press-release/arena-announces-corporate-update-and-reports-first-quarter-2020-financial-results
https://www.nasdaq.com/press-release/arena-pharmaceuticals-to-present-at-the-bank-of-america-securities-healthcare
https://www.nasdaq.com/press-release/arena-pharmaceuticals-to-release-first-quarter-2020-financial-results-and-provide
https://www.nasdaq.com/press-release/arena-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-1
https://www.nasdaq.com/press-release/arena-pharmaceuticals-to-present-at-the-19th-annual-needham-virtual-healthcare
https://www.nasdaq.com/press-release/arena-pharmaceuticals-announces-positive-topline-data-for-new-development-program
https://www.nasdaq.com/press-release/arena-pharmaceuticals-names-james-c.-mullen-as-an-independent-senior-advisor-2020-03
https://www.nasdaq.com/press-release/arena-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-0
https://www.nasdaq.com/press-release/arena-announces-management-and-program-updates-and-reports-fourth-quarter-and-full
https://www.nasdaq.com/press-release/arena-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2020
https://www.nasdaq.com/press-release/arena-pharmaceuticals-to-present-at-the-upcoming-investor-conferences-2020-02-20
https://www.nasdaq.com/press-release/arena-pharmaceuticals-to-release-fourth-quarter-full-year-2019-financial-results-and
https://www.nasdaq.com/press-release/arena-pharmaceuticals-presence-at-the-european-crohns-and-colitis-organisation-ecco
https://www.nasdaq.com/press-release/fda-grants-fast-track-designation-to-arena-pharmaceuticals-apd418-for-development-in
https://www.nasdaq.com/press-release/arena-pharmaceuticals-appoints-joan-schmidt-as-executive-vice-president-general
https://www.nasdaq.com/press-release/arena-pharmaceuticals-to-present-at-the-38th-annual-j.p.-morgan-healthcare-conference
https://www.nasdaq.com/press-release/arena-pharmaceuticals-highlights-strategic-plan-driving-near-and-long-term-growth
https://www.nasdaq.com/press-release/arena-pharmaceuticals-to-participate-in-upcoming-investor-conferences-2019-11-26
https://www.nasdaq.com/press-release/california-life-sciences-association-honors-arena-pharmaceuticals-at-the-pantheon
https://www.nasdaq.com/press-release/arena-pharmaceuticals-presented-new-data-highlighting-the-human-mass-balance-and
https://www.nasdaq.com/press-release/arena-pharmaceuticals-to-present-at-upcoming-investor-conferences-2019-11-05
https://www.nasdaq.com/press-release/arena-pharmaceuticals-to-release-third-quarter-2019-financial-results-and-provide
https://www.nasdaq.com/press-release/arena-pharmaceuticals-announces-first-subject-dosed-in-advise-phase-2-trial
https://www.nasdaq.com/press-release/arena-pharmaceuticals-presented-new-data-analyses-demonstrating-the-long-term-safety
https://www.nasdaq.com/press-release/arena-pharmaceuticals-presence-at-united-european-gastroenterology-week-bolsters
https://www.nasdaq.com/press-release/arena-pharmaceuticals-to-present-new-preclinical-atopic-dermatitis-data-for-etrasimod
https://www.nasdaq.com/press-release/arena-pharmaceuticals-presented-new-patient-reported-outcomes-data-for-olorinab-at
https://www.nasdaq.com/press-release/arena-pharmaceuticals-to-participate-in-upcoming-investor-conferences-2019-08-28
https://www.nasdaq.com/press-release/arena-reports-second-quarter-financial-results-with-strong-liquidity-position-and
https://www.nasdaq.com/press-release/arena-pharmaceuticals-to-release-second-quarter-2019-financial-results-and-provide
https://www.nasdaq.com/press-release/arena-pharmaceuticals-announces-first-subject-dosed-in-captivate-phase-2-trial
https://www.nasdaq.com/press-release/arena-pharmaceuticals-announces-first-subject-dosed-in-elevate-uc-52-global-phase-3
https://www.nasdaq.com/press-release/arena-pharmaceuticals-present-jmp-securities-life-sciences-conference-june-19-2019-06
https://www.nasdaq.com/press-release/arena-pharmaceuticals-presence-digestive-disease-week-ddw-reinforces-commitment
